Rivastigmine: An update on therapeutic efficacy in Alzheimer's disease and other conditions

Current Medical Research and Opinion

Volumn 19, Issue 2, 2003, Pages 69-82

  Gabelli, Carlo ^a,b  

^a Res Consortium L Amaducci CRIC   (Italy)

^b CRIC   (Italy)

Author keywords

Alzheimer's disease; Dementia; Rivastigmine; Synucleinopathies

Indexed keywords

ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; HYPNOTIC SEDATIVE AGENT; NEUROLEPTIC AGENT; RIVASTIGMINE;

AGED; ALZHEIMER DISEASE; BEHAVIOR DISORDER; CAREGIVER; CLINICAL TRIAL; COGNITION; COST CONTROL; DAILY LIFE ACTIVITY; DIFFUSE LEWY BODY DISEASE; DRUG COST; DRUG EFFICACY; DRUG INDICATION; FEMALE; HUMAN; INSTITUTIONALIZATION; MALE; META ANALYSIS; MULTIINFARCT DEMENTIA; PARKINSON DISEASE; PHYSICIAN; PRACTICE GUIDELINE; PROBABILITY; REVIEW; TASK PERFORMANCE;

ACTIVITIES OF DAILY LIVING; ALZHEIMER DISEASE; CARBAMATES; COGNITION; DISEASE PROGRESSION; ECONOMICS, PHARMACEUTICAL; HUMANS; MENTAL DISORDERS; META-ANALYSIS; NEUROPROTECTIVE AGENTS; PHENYLCARBAMATES; RISK FACTORS; TREATMENT OUTCOME;

EID: 0037960260     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079902125001452     Document Type: Review

References (46)

1. Alzheimer's Association. Prevalence of Alzheimer's disease in the USA. Data presented at the 8th International Conference on Alzheimer's Disease and Related Disorders. Stockholm, Sweden, 20-25 July 2002
2. Rocca WA, Bonaiuto S, Lippi A, et al. Prevalence of clinically diagnosed Alzheimer's disease and other dementing disorders: a door-to-door survey in Appignano, Macerata Province, Italy. Neurology 1990;40:626-31
3. Lemière J, Van Gool D, Dom R. Treatment of Alzheimer's disease: an evaluation of the cholinergic approach. Acta Neurolog Belg 1999;99:96-106
4. Mesulam M, Guillozet A, Shaw P, Quinn B. Widely spread butyrylcholinesterase can hydrolyze acetylcholine in the normal and Alzheimer brain. Neurobiol Dis 2002;9:88-93
5. Wright CI, Geula C, Mesulam MM. Neurological cholinesterases in the normal brain and in Alzheimer's disease: relationship to plaques, tangles and patterns of selective vulnerability. Ann Neurol 1993;34:373-84
6. Costa JF, Anand R, Cutler NR, et al. Correlation between cognitive effects and level of acetylcholine inhibition in a trial of rivastigmine in Alzheimer's patients. Proceedings of the American Psychiatric Association; poster presentation 1999
7. Weinstock M. Selectivity of cholinesterase inhibition. Clinical implications for the treatment of Alzheimer's disease. CNS Drugs 1999;12:307-23
8. Jann MW. Rivastigmine, a new-generation cholinesterase inhibitor for the treatment of Alzheimer's disease. Pharmacotherapy 2000;20:1-12
9. Birks J, Grimley EJ, Iakovidou V, Tsolaki M. Rivastigmine for Alzheimer's disease. Cochrane review. In: Cochrane Library, Issue 4, 2001
10. Darreh-Shori T, Almkvist O, Guan ZZ, et al. Sustained cholinesterase inhibition in AD patients receiving rivastigmine for 12 months. Neurology 2002;59:563-72
11. Venneri A, Shanks MF, Staff RT, et al. Cerebral blood flow and cognitive responses to rivastigmine treatment in Alzheimer's disease. Neuroreport 2001;13:1-5
12. Corey-Bloom J, Anand R, Veach J for the ENA 713 B352 Study Group. A randomised trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. Int J Geriatr Psychopharmacol 1998;1:55-65
13. Farlow M, Anand R, Messina J, et al. A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's Disease. Eur Neurol 2000;44:236-41
14. Grossberg G, Irwin P, Satlin A, et al. Rivastigmine in Alzheimer's disease: efficacy over two years. Am J Geriatr Psychiatry in press
15. Doraiswamy PM, Krishnan KRR, Anand R, et al. Long-term effects of rivastigmine in moderately severe Alzheimer's disease. Does early initiation of therapy offer sustained benefits? Prog Neuropsychopharmacol Biol Psychiatry 2001;26:705-12
16. Robert P. Understanding and managing behavioural symptoms in Alzheimer's disease and related dementias: focus on rivastigmine. Curr Med Res Opin 2002;18:156-71
17. Cummings J, Anand R, Koumaras B, Hartman R. Rivastigmine provides behavioral benefits to Alzheimer's disease patients residing in a nursing home: findings from a 26-week trial. Neurology 2000;54(Suppl 3):A468
18. Messina J, Koumaras B, Hartman R. Treatment with rivastigmine reduces the need for psychotropic medications in patients with Alzheimer's disease residing in long-term care facilities. Poster presented at the 3rd Annual International Meeting for the College of Psychiatric and Neurologic Pharmacists, Washington, DC, USA. April 6-9 2000
19. Etemad B, Anand R, Hartman R. Behavioural and cognitive benefits of rivastigmine in nursing home patients with Alzheimer's disease and related dementias: a 26-week follow-up. Poster presented at the 9th International Congress of the International Psychogeriatric Association, Nice, France, September 2001
20. Rösler M, Retz W, Retz-Junginger P, Dennler HJ. Effects of two-year treatment with the cholinesterase inhibitor rivastigmine on behavioural symptoms in Alzheimer's disease. Behav Neurol 1998;11:211-16
21. Rösler M, Anand R, Cicin-Sain A, et al. Efficacy and safety of rivastigmine in patients with Alzheimer's Disease: international, randomised, controlled trial. BMJ 1999;318:633-40
22. Committee for Proprietary Medicinal Products. Note for guidance on medicinal products in the treatment of Alzheimer's disease. CPMP/EWP/553/95 September 1997
23. Kumar V, Anand R, Messina J, et al. An efficacy and safety analysis of Exelon® Alzheimer's disease patients with concurrent vascular risk factors. Eur J Neurol 2000;7:159-69
24. Kumar V, Messina J, Hartman R, Anand R. Long-term cognitive benefits of rivastigmine in Alzheimer's disease patients with vascular risk. Poster presented at the 6th International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy, Stockholm, Sweden, 5-8 April 2000 (Abstr 38A)
25. Erkinjuntti T, Skoog I, Lane R, Andrews C. Efficacy of rivastigmine in patients with Alzheimer's disease and concurrent hypertension. Int J Clin Pract 2002;56:791-6
26. Farlow MR, Hake A, Messina J, et al. Response of patients with Alzheimer disease to rivastigmine treatment is predicted by the rate of disease progression. Arch Neurol 2001;58:417-22
27. Lamb HM, Goa KL. Rivastigmine - a pharmacoeconomic review of its use in Alzheimer's Disease. Pharmacoeconomics 2001;19:303-18
28. Fenn P, Gray A. Estimating the long term cost savings from the treatment of Alzheimer's Disease: a modelling approach. Pharmacoeconomics 1999;2:165-74
29. Brooks E, Deal L. The effect of rivastigmine on the direct and indirect costs of Alzheimer's disease. Value Health 2000;3:79
30. Hauber AB, Gnanasakthy A, Mauskopf JA. Savings in the cost of caring for patients with Alzheimer's disease in Canada: an analysis of treatment with rivastigmine. Clin Ther 2000;22:439-51
31. Hauber AB, Gnanasakthy A, Snyder EH, et al. Potential savings in the cost of caring for Alzheimer's disease: treatment with rivastigmine. Pharmacoeconomics 2000;17:351-60
32. Szucs T, Belisari A, Mantovani L. Alzheimer's disease in Italia: benefici economici dell'impiego terapeutico di Exelon®. Data on file, Novartis Farma, Origgio (Italia)
33. Galvin JE, Lee VM, Trojanowski JQ. Synucleinopathies: clinical and pathological implications. Arch Neurol 2001;58:186-90
34. Perry EK, Haroutunian V, Davis KL, et al. Neocortical cholinergic activities differentiate Lewy body dementia from classical Alzheimer's disease. Neuroreport 1994;5:747-9
35. Sakurada T, Alufuzoff I, Winblad B, Nordberg A. Substance P-like immunoreactivity, choline acetyltransferase activity and cholinergic muscarinic receptors in Alzheimer's disease and multi-infarct dementia. Brain Res 1990;521:329-32
36. Kalaria RN, Ballard CG, Ince PG, et al. Multiple substrates of late-onset dementia: implications for brain protection. Novartis Found Symp 2001;235:49-60
37. McKeith IG, Grace JB, Walker Z, et al. Rivastigmine in the treatment of dementia with Lewy bodies: preliminary findings from an open trial. Int J Geriatr Psychiatry 2000;15:387-92
38. McKeith I, Del Ser T, Spano P, et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet 2000;356:2031-6
39. Del Ser T, McKeith I, Anand R, et al. Dementia with Lewy bodies: findings from an international multicentre study. Int J Geriatr Psychiatry 2000;15:1034-45
40. Wesnes K, McKeith IG, Ferrara R, et al. Effects of rivastigmine on cognitive function in dementia with Lewy bodies: a randomised placebo-controlled international study using the cognitive drug research computerised assessment system. Dement Geriatr Cogn Disord 2002;13:183-92
41. Grace J, Daniel S, Stevens T, et al. Long-term use of rivastigmine in patients with dementia with Lewy bodies: an open-label trial. Intern Psychogeriatr 2001;13:199-205
42. Reading PJ, Luce AK, McKeith IG. Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: preliminary findings from an open trial. Mov Disord 2001;16:1171-4
43. Giladi N, Shabati H, Gurevich, et al. Rivastigmine (Exelon) for dementia in patients with Parkinson's disease. Acta Neurol Scand, in press
44. Van Laar T, de Vries JJ, Nakhosteen A, Leenders KL. Rivastigmine as anti-psychotic treatment in patients with Parkinson's disease. Poster presented at the 14th International Conference on Parkinson's Disease, Helsinki, Finland, May 2001
45. Moretti R, Torre P, Antonello RM, Cazzato G. Rivastigmine in subcortical vascular dementia: a comparison trial on efficacy and tolerability for 12 months follow-up. Eur J Neurol 2001;8:361-2
46. Moretti R, Torre P, Antonello RM, Cazzato G, Bava A. Rivastigmine in subcortical vascular dementia: an open 22-month study. J Neurol Sci 2002;203-4:141-6